MAIA Biotechnology Inc.
MAIA Biotechnology, Inc., together with its subsidiaries, immuno-oncology company, focuses on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer. Its lead program is THIO, a potential cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positiv… Read more
MAIA Biotechnology Inc. (MAIA) - Net Assets
Latest net assets as of September 2025: $41.67K USD
Based on the latest financial reports, MAIA Biotechnology Inc. (MAIA) has net assets worth $41.67K USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($11.78 Million) and total liabilities ($11.74 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $41.67K |
| % of Total Assets | 0.35% |
| Annual Growth Rate | 22.36% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 341.66 |
MAIA Biotechnology Inc. - Net Assets Trend (2019–2024)
This chart illustrates how MAIA Biotechnology Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for MAIA Biotechnology Inc. (2019–2024)
The table below shows the annual net assets of MAIA Biotechnology Inc. from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $3.63 Million | +661.16% |
| 2023-12-31 | $477.51K | -94.39% |
| 2022-12-31 | $8.51 Million | -7.33% |
| 2021-12-31 | $9.18 Million | +668.04% |
| 2020-12-31 | $-1.62 Million | -222.00% |
| 2019-12-31 | $1.32 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to MAIA Biotechnology Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7793738000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.62K | 0.07% |
| Other Comprehensive Income | $-30.61K | -0.84% |
| Other Components | $90.90 Million | 2500.87% |
| Total Equity | $3.63 Million | 100.00% |
MAIA Biotechnology Inc. Competitors by Market Cap
The table below lists competitors of MAIA Biotechnology Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Citizens Bancshares Corp
PINK:CZBS
|
$48.22 Million |
|
Carnaby Resources Ltd
AU:CNB
|
$48.22 Million |
|
PADAUK Technology Co. Ltd
TWO:6716
|
$48.23 Million |
|
Shenzhen Zhongzhuang Construction Group Co Ltd
SHE:002822
|
$48.24 Million |
|
Bio-FD&C Co. Ltd.
KQ:251120
|
$48.22 Million |
|
Ratnaveer Precision Engineering Ltd
NSE:RATNAVEER
|
$48.20 Million |
|
Leo Lithium Limited
PINK:LLLAF
|
$48.19 Million |
|
Plastron Precision Co Ltd
TWO:6185
|
$48.19 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in MAIA Biotechnology Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 477,511 to 3,634,636, a change of 3,157,125 (661.2%).
- Net loss of 23,254,656 reduced equity.
- New share issuances of 18,754,708 increased equity.
- Other comprehensive income decreased equity by 14,355.
- Other factors increased equity by 7,671,428.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-23.25 Million | -639.81% |
| Share Issuances | $18.75 Million | +516.0% |
| Other Comprehensive Income | $-14.36K | -0.39% |
| Other Changes | $7.67 Million | +211.06% |
| Total Change | $- | 661.16% |
Book Value vs Market Value Analysis
This analysis compares MAIA Biotechnology Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 9.16x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-0.02 | $1.50 | x |
| 2020-12-31 | $-0.31 | $1.50 | x |
| 2021-12-31 | $0.86 | $1.50 | x |
| 2022-12-31 | $0.92 | $1.50 | x |
| 2023-12-31 | $0.04 | $1.50 | x |
| 2024-12-31 | $0.16 | $1.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently MAIA Biotechnology Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -639.81%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 2.79x
- Recent ROE (-639.81%) is above the historical average (-850.36%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-6.48 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-6.30 Million |
| 2021 | -136.19% | 0.00% | 0.00x | 1.23x | $-13.42 Million |
| 2022 | -185.35% | 0.00% | 0.00x | 1.41x | $-16.62 Million |
| 2023 | -4140.83% | 0.00% | 0.00x | 15.85x | $-19.82 Million |
| 2024 | -639.81% | 0.00% | 0.00x | 2.79x | $-23.62 Million |
Industry Comparison
This section compares MAIA Biotechnology Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| MAIA Biotechnology Inc. (MAIA) | $41.67K | 0.00% | 281.75x | $48.22 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |